Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. 2002

Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology, Tsukuba 305-8566, Japan.

A mammalian-like sugar moiety was created in glycoprotein by Saccharomyces cerevisiae in combination with bacterial alpha-mannosidase to produce a more economic enzyme replacement therapy for patients with Fabry disease. We introduced the human alpha-galactosidase A (alpha-GalA) gene into an S. cerevisiae mutant that was deficient in the outer chains of N-linked mannan. The recombinant alpha-GalA contained both neutral (Man(8)GlcNAc(2)) and acidic ([Man-P](1-2)Man(8)GlcNAc(2)) sugar chains. Because an efficient incorporation of alpha-GalA into lysosomes of human cells requires mannose-6-phosphate (Man-6-P) residues that should be recognized by the specific receptor, we trimmed down the sugar chains of the alpha-GalA by a newly isolated bacterial alpha-mannosidase. Treatment of the alpha-GalA with the alpha-mannosidase resulted in the exposure of a Man-6-P residue on a nonreduced end of oligosaccharide chains after the removal of phosphodiester-linked nonreduced-end mannose. The treated alpha-GalA was efficiently incorporated into fibroblasts derived from patients with Fabry disease. The uptake was three to four times higher than that of the nontreated alpha-GalA and was inhibited by the addition of 5 mM Man-6-P. Incorporated alpha-GalA was targeted to the lysosome, and hydrolyzed ceramide trihexoside accumulated in the Fabry fibroblasts after 5 days. This method provides an effective and economic therapy for many lysosomal disorders, including Fabry disease.

UI MeSH Term Description Entries
D008247 Lysosomes A class of morphologically heterogeneous cytoplasmic particles in animal and plant tissues characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured or undergoes MEMBRANE FUSION. (From Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed). Autolysosome,Autolysosomes,Lysosome
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009844 Oligosaccharides Carbohydrates consisting of between two (DISACCHARIDES) and ten MONOSACCHARIDES connected by either an alpha- or beta-glycosidic link. They are found throughout nature in both the free and bound form. Oligosaccharide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002240 Carbohydrate Sequence The sequence of carbohydrates within POLYSACCHARIDES; GLYCOPROTEINS; and GLYCOLIPIDS. Carbohydrate Sequences,Sequence, Carbohydrate,Sequences, Carbohydrate
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000519 alpha-Galactosidase An enzyme that catalyzes the hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-galactosides including galactose oligosaccharides, galactomannans, and galactolipids. Beano,Melibiase,alpha-D-Galactopyranosidase,alpha-D-Galactosidase,alpha-Galactisidase,alpha-Galactosidase A,alpha-Galactosidases,alpha D Galactopyranosidase,alpha D Galactosidase,alpha Galactisidase,alpha Galactosidase,alpha Galactosidase A,alpha Galactosidases
D000795 Fabry Disease An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders. Anderson-Fabry Disease,Angiokeratoma Corporis Diffusum,Angiokeratoma Diffuse,Angiokeratoma, Diffuse,Ceramide Trihexosidase Deficiency,Fabry's Disease,GLA Deficiency,Hereditary Dystopic Lipidosis,alpha-Galactosidase A Deficiency,alpha-Galactosidase A Deficiency Disease,Anderson Fabry Disease,Deficiency, Ceramide Trihexosidase,Deficiency, GLA,Deficiency, alpha-Galactosidase A,Diffuse Angiokeratoma,Lipidosis, Hereditary Dystopic,alpha Galactosidase A Deficiency,alpha Galactosidase A Deficiency Disease
D012441 Saccharomyces cerevisiae A species of the genus SACCHAROMYCES, family Saccharomycetaceae, order Saccharomycetales, known as "baker's" or "brewer's" yeast. The dried form is used as a dietary supplement. Baker's Yeast,Brewer's Yeast,Candida robusta,S. cerevisiae,Saccharomyces capensis,Saccharomyces italicus,Saccharomyces oviformis,Saccharomyces uvarum var. melibiosus,Yeast, Baker's,Yeast, Brewer's,Baker Yeast,S cerevisiae,Baker's Yeasts,Yeast, Baker

Related Publications

Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
January 2001, Contributions to nephrology,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
January 1980, Birth defects original article series,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
July 2004, Expert opinion on biological therapy,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
September 2005, Biochimica et biophysica acta,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
January 2003, American journal of human genetics,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
November 2003, Journal of the European Academy of Dermatology and Venereology : JEADV,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
January 2001, American journal of human genetics,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
January 2001, Journal of inherited metabolic disease,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
July 2016, The Cochrane database of systematic reviews,
Yasunori Chiba, and Hitoshi Sakuraba, and Masaharu Kotani, and Ryoichi Kase, and Kazuo Kobayashi, and Makoto Takeuchi, and Satoshi Ogasawara, and Yutaka Maruyama, and Tasuku Nakajima, and Yuki Takaoka, and Yoshifumi Jigami
August 2001, Lancet (London, England),
Copied contents to your clipboard!